Stock Price & Analysis

The S1 support level for ITOS Stock is $7.04 ,The R1 resistant level for ITOS Stock is $7.56.

As of the end of day on 2025-02-26, the price of ITOS Stock was $7.07.

The target price for ITOS Stock according to analyst rating is 20.00, with the highest price target at 21.00 and the lowest at 19.00. Analysts have a Moderate Buy rating on ITOS Stock overall.

The market cap of ITOS is $255.0M.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.

ITOS has a total of 157 employees.